Special Issue

Small Extracellular Vesicles: A Novel Avenue for Brain Tumor Management

Message from the Guest Editors

It is quite ascertained that extracellular vesicles (EVs) mediate cell-to-cell communication in cancer. In the brain, EVs are secreted by not only tumor cells, but also all the other existing cell types. Recent studies reveal that miRNAs are secreted in the body fluids as EV cargo and are able to influence the recipient cell phenotype, miRNA contained in EVs are promising candidate liquid biomarkers of great significance for cancer. In this scenario, the isolation of miRNAs from EVs to identify molecular signatures for brain tumor early diagnosis could possibly replace the more costly and invasive tissue biopsy procedures in the near future. The purpose of this Special Issue is to attract articles (both original research articles and reviews) from experts in the field of EV research in the brain tumor that can take innovative approaches or express novel views on the multifaceted world of EVs in cancer biology, progression and therapy.

Guest Editors

Dr. Igea D'Agnano

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

Dr. Ingrid Cifola

Institute for Biomedical Technologies (ITB), National Research Council (CNR), Segrate, Milan, Italy

Deadline for manuscript submissions

closed (30 June 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/82875

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).